Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. The Company's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which were jointly developed by Innoviva and GSK. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of vilanterol (VI), a long-acting beta2-agonist, and fluticasone furoate, an inhaled corticosteroid, delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of umeclidinium, a long-acting muscarinic antagonist, and vilanterol (VI), a long-acting beta2-agonist for the treatment of chronic obstructive pulmonary diseases.

Company Growth (employees)
Brisbane, US
Size (employees)
12 (est)-14%
Innoviva was founded in 1996 and is headquartered in Brisbane, US

Innoviva Office Locations

Innoviva has an office in Brisbane
Brisbane, US (HQ)
500 2000 Sierra Point Pkwy
Show all (1)

Innoviva Financials and Metrics

Innoviva Financials

Innoviva's revenue was reported to be $133.6 m in FY, 2016

Revenue (Q2, 2017)

58.6 m

Net income (Q2, 2017)

35.1 m

EBIT (Q2, 2017)

47.8 m

Market capitalization (31-Oct-2017)

1.3 b

Closing share price (31-Oct-2017)


Cash (30-Jun-2017)

127.6 m
Innoviva's current market capitalization is $1.3 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


4.8 m8.4 m53.9 m133.6 m

Revenue growth, %


R&D expense

1.4 m

General and administrative expense

23.2 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


165 k934 k999 k6.9 m10.7 m13.6 m24.2 m32.5 m33.3 m40.5 m58.6 m

Cost of goods sold

188 k

Gross profit

(23 k)

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


143.5 m96.8 m159.2 m118 m


10.4 m814 k766 k

Current Assets

483.2 m252.2 m214.3 m198 m


10.2 m324 k221 k368 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


171.9 m125.3 m208.1 m119.6 m141.2 m149.6 m78.7 m151.8 m112.9 m93.2 m159.8 m127.6 m

Accounts Receivable

450 k


9 m11 m

Current Assets

522.3 m389.2 m353.2 m273.5 m262.4 m244 m223.8 m196.7 m190.4 m186.1 m214.4 m198.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(170.7 m)(168.5 m)(18.8 m)59.5 m

Depreciation and Amortization

8.2 m12.2 m13.9 m14 m


(3.1 m)(1.9 m)

Accounts Payable

1.6 m(7.7 m)818 k(690 k)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(47 m)(67.7 m)(63.6 m)(21.3 m)(10.7 m)(18.5 m)(23.1 m)4.4 m19 m34.1 m16.8 m52 m

Depreciation and Amortization

7 m10.4 m3.5 m7 m10.5 m3.5 m7 m

Accounts Payable

1.8 m573 k1 m462 k154 k(242 k)(681 k)(290 k)2.2 m149 k

Cash From Operating Activities

558 k3.2 m7.3 m19.7 m39.9 m27.8 m50.4 m
USDY, 2017


4.2 m

Financial Leverage

-1.3 x
Show all financial metrics

Innoviva Operating Metrics

FY, 2016

Patents Issued

Show all operating metrics

Innoviva Market Value History

Innoviva's Web-traffic and Trends

Innoviva Company Life and Culture

You may also be interested in